(Q38692683)

5 September 2017

title

Cediranib in ovarian cancer: state of the art and future perspectives (English)

1 reference

5 September 2017

1 reference

Ilary Ruscito

1

0 references

Maria Luisa Gasparri

object named as

Maria Luisa Gasparri

2

0 references

Claudia Marchetti

object named as

Claudia Marchetti

3

0 references

Andrea Papadia

object named as

Andrea Papadia

9

0 references

author name string

Caterina De Medici

4

1 reference

5 September 2017

Carlotta Bracchi

5

1 reference

5 September 2017

Innocenza Palaia

6

1 reference

5 September 2017

Sara Imboden

7

1 reference

5 September 2017

Michael D Mueller

8

1 reference

5 September 2017

Ludovico Muzii

10

1 reference

5 September 2017

Pierluigi Benedetti Panici

11

1 reference

5 September 2017

publication date

11 January 2016

1 reference

5 September 2017

1 reference

5 September 2017

volume

37

1 reference

5 September 2017

issue

3

1 reference

5 September 2017

page(s)

2833-2839

1 reference

https://scigraph.springernature.com/pub.10.1007/s13277-015-4781-4

5 September 2017

exact match

0 references

cites work

Cancer statistics, 2015

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4781-4

Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4781-4

Isolation of a tumor factor responsible for angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4781-4

A phase 3 trial of bevacizumab in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4781-4

Incorporation of bevacizumab in the primary treatment of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4781-4

Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4781-4

Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4781-4

A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4781-4

Monoclonal antibodies therapies for ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4781-4

Monoclonal antibodies in gynecological cancer: a critical point of view

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4781-4

Current knowledge and open issues regarding bevacizumab in gynaecological neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4781-4

Advances in anti-angiogenic agents for ovarian cancer treatment: The role of trebananib (AMG 386).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4781-4

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4781-4

The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4781-4

Cediranib combined with chemotherapy reduces tumor dissemination and prolongs the survival of mice bearing patient-derived ovarian cancer xenografts with different responsiveness to cisplatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4781-4

Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4781-4

Olaparib, PARP1 inhibitor in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4781-4

A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4781-4

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4781-4

Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4781-4

A phase II study of cediranib as palliative treatment in patients with symptomatic malignant ascites or pleural effusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4781-4

A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: a trial of the Princess Margaret, Chicago and California Phase II Consortia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4781-4

Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4781-4

The biology of VEGF and its receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4781-4

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4781-4

The tyrosine kinase inhibitor, AZD2171, inhibits vascular endothelial growth factor receptor signaling and growth of anaplastic thyroid cancer in an orthotopic nude mouse model

21 January 2018

1 reference

12 December 2020

PARP inhibition: A promising therapeutic target in ovarian cancer

1 reference

12 December 2020

Specific binding of vasculotropin to bovine brain capillary endothelial cells

1 reference

12 December 2020

Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumours

1 reference

12 December 2020

10.1007/S13277-015-4781-4

Identifiers

DOI

1 reference

Dimensions Publication ID

5 September 2017

1009328495

0 references

1 reference